{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
nonoxynol-9
to a specific field?
Status:
Possibly Marketed Outside US
Source:
Le-Blen Nano Collagen Peptide Serum by LeBlen Beauty Inc
Source URL:
First approved in 1999
Source:
Dermal-Soothe by Vetoquinol USA, Inc.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(1999)
Source URL:
First approved in 1999
Source:
NDA020805
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 334
(2022)
Source URL:
First approved in 1998
Source:
M022
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Tea Tree Oil by Fujian Meigulin Bio-Technique Co., Ltd.
Source URL:
First approved in 1998
Source:
21 CFR 358H
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 347
(1997)
Source URL:
First approved in 1997
Source:
21 CFR 347
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT01927848: Phase 4 Interventional Completed Knee Related Walking Limitations
(2013)
Source URL:
First approved in 1997
Source:
21 CFR 347
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03192371: Phase 4 Interventional Withdrawn Virus Diseases
(2018)
Source URL:
First approved in 1997
Source:
BLA103334
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NDA020701
(1997)
Source URL:
First approved in 1997
Source:
NDA020701
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2011)
Source URL:
First approved in 1997
Source:
NaturVet ArthriSoothe by The Garmon Corporation
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03855176: Phase 4 Interventional Completed Hepatitis A
(2017)
Source URL:
First approved in 1996
Source:
BLA103606
Source URL:
Class:
STRUCTURALLY DIVERSE